|Bid||91.85 x N/A|
|Ask||91.86 x N/A|
|Day's Range||89.62 - 91.99|
|52 Week Range||57.18 - 96.47|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||76.54|
|Earnings Date||Apr 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 28, 2019|
|1y Target Est||73.49|
Heidelberg, Germany--(Newsfile Corp. - November 8, 2019) - Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol® for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong ...
Thanks to a big IPO on the Hong Kong Stock Exchange, a Chinese couple have become China's richest husband-and-wife team. The initial public offering of Hansoh Pharmaceutical Group, which closed up 37.3% on its debut on Friday, made Chairwoman Zhong Huijuan China's third-richest woman. Zhong's husband, Sun Piaoyang, is already worth $9.8 billion, according to Forbes.
* PREVIOUS TRADING SESSION MOVES: * SSEC +2.4 pct, CSI300 +2.8 pct, HSI +1.1 pct * HK- Shanghai Connect daily quota used 4.3 pct, Shanghai- HK daily quota used 2.6 pct * HK- Shenzhen Connect daily ...
SALT LAKE CITY and SHANGHAI , April 8, 2019 /PRNewswire/ -- LSK BioPharma (or "LSKB"), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or "Hengrui"), ...